Gilead Sciences (GILD) Net Cash Flow (2009 - 2026)

Gilead Sciences has reported Net Cash Flow for 18 years, with the latest figure at $75.0 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 103.6% year-over-year to $75.0 million; the trailing twelve-month figure through Mar 2026 stood at -$360.0 million (down 111.21% YoY), and the FY2025 full-year result was -$2.5 billion, down 163.84% from the prior year.
• Net Cash Flow for Q1 2026 stood at $75.0 million, down from $229.0 million in the prior quarter.
• The five-year high for Net Cash Flow was $5.0 billion in Q4 2024, with the low at -$2.9 billion in Q2 2025.
• Historically, Net Cash Flow has averaged $132.6 million across 5 years, with a median of $75.0 million in 2026.
• The largest YoY upside for Net Cash Flow was 31614.29% in 2024 against a maximum downside of 356.63% in 2024.
• Gilead Sciences' Net Cash Flow stood at $638.0 million in 2022, then sank by 46.24% to $343.0 million in 2023, then soared by 1360.64% to $5.0 billion in 2024, then slumped by 95.43% to $229.0 million in 2025, then tumbled by 67.25% to $75.0 million in 2026.
• The last three Net Cash Flow figures came in at $75.0 million (Q1 2026), $229.0 million (Q4 2025), and $2.2 billion (Q3 2025), per Business Quant data.